Show simple item record

dc.contributor.authorNic Lochlainn, Laura M
dc.contributor.authorde Gier, Brechje
dc.contributor.authorvan der Maas, Nicoline
dc.contributor.authorStrebel, Peter M
dc.contributor.authorGoodman, Tracey
dc.contributor.authorvan Binnendijk, Rob S
dc.contributor.authorde Melker, Hester E
dc.contributor.authorHahné, Susan J M
dc.date.accessioned2019-11-03T16:30:34Z
dc.date.available2019-11-03T16:30:34Z
dc.date.issued2019-11-01
dc.identifier.issn1474-4457
dc.identifier.pmid31548079
dc.identifier.doi10.1016/S1473-3099(19)30395-0
dc.identifier.urihttp://hdl.handle.net/10029/623448
dc.description.abstractOur search identified 1156 studies, of which 1071 were screened for eligibility. 351 were eligible for full-text screening, and data from 56 studies that met all inclusion criteria were used for analysis. The proportion of infants who seroconverted increased from 50% (95% CI 29-71) for those vaccinated with MCV1 at 4 months of age to 85% (69-97) for those were vaccinated at 8 months. The pooled geometric mean titre ratio for infants aged 4-8 months vaccinated with MCV1 compared with infants vaccinated with MCV1 at age 9 months or older was 0·46 (95% CI 0·33-0·66; I2=99·9%, p<0·0001). Only one study reported on avidity and suggested that there was lower avidity and a shorter duration of immunity following MCV1 administration at 6 months of age than at 9 months of age (p=0·0016) or 12 months of age (p<0·001). No effect of age at MCV1 administration on cellular immunity was found. One study reported that vaccine efficacy against laboratory-confirmed measles virus infection was 94% (95% CI 74-98) in infants vaccinated with MCV1 at 4·5 months of age. The pooled vaccine effectiveness of MCV1 in infants younger than 9 months against measles was 58% (95% CI 9-80; I2=84·9%, p<0·0001). The pooled vaccine effectiveness estimate from within-study comparisons of infants younger than 9 months vaccinated with MCV1 were 51% (95% CI -44 to 83; I2=92·3%, p<0·0001), and for those aged 9 months and older at vaccination it was 83% (76-88; I2=93·8%, p<0·0001). No differences in the risk of adverse events after MCV1 administration were found between infants younger than 9 months and those aged 9 months of older. Overall, the quality of evidence ranged from moderate to very low.en_US
dc.language.isoenen_US
dc.titleImmunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis.en_US
dc.typeArticleen_US
dc.identifier.journalThe Lancet Infect Dis 2019; 19(11):1235-45en_US
dc.source.journaltitleThe Lancet. Infectious diseases


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record